FibroBiologics, Inc.
FBLG
$0.95
$0.022.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.36% | 0.09% | 14.21% | 22.30% | 31.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.97% | 21.19% | 42.10% | 43.54% | 47.09% |
| Operating Income | -15.97% | -21.19% | -42.10% | -43.54% | -47.09% |
| Income Before Tax | -143.64% | -67.06% | -4.06% | 32.09% | 65.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -143.64% | -67.06% | -4.06% | 32.09% | 65.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -143.64% | -67.06% | -4.06% | 32.09% | 65.97% |
| EBIT | -15.97% | -21.19% | -42.10% | -43.54% | -47.09% |
| EBITDA | -15.60% | -20.79% | -41.90% | -43.26% | -46.53% |
| EPS Basic | -79.36% | -25.02% | 21.37% | 46.67% | 73.09% |
| Normalized Basic EPS | -90.11% | -21.67% | 23.31% | 48.43% | 74.61% |
| EPS Diluted | -79.36% | -25.02% | 21.37% | 46.67% | 73.09% |
| Normalized Diluted EPS | -90.11% | -21.67% | 23.31% | 48.43% | 74.61% |
| Average Basic Shares Outstanding | 42.47% | 9.23% | -6.38% | -10.21% | -11.84% |
| Average Diluted Shares Outstanding | 42.47% | 9.23% | -6.38% | -10.21% | -11.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |